CLINICAL TRIALS PROFILE FOR RHOPRESSA
✉ Email this page to a colleague
All Clinical Trials for RHOPRESSA
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT03808688 ↗ | Study of Rhopressa® for the Reduction of Elevated Intraocular Pressure in Patients With Glaucoma or Ocular Hypertension in a Real-world Setting | Completed | Aerie Pharmaceuticals | Phase 4 | 2018-12-27 | To evaluate the IOP lowering efficacy of netarsudil ophthalmic solution 0.02% when used as monotherapy or when used concomitantly with other IOP-lowering agents in subjects with elevated IOP due to open angle glaucoma or ocular hypertension in a real-world clinical setting. The study is an open-label design. The patients will receive treatment for 12 weeks. |
| NCT03971357 ↗ | Trial of Netarsudil for Acceleration of Corneal Endothelial Restoration | Terminated | Cornea Research Foundation of America | Phase 2/Phase 3 | 2019-07-22 | Subjects with Fuchs dystrophy will be randomized to use either netarsudil or placebo eye drops to determine if the use of netarsudil accelerates migration of host peripheral corneal endothelial cells to restore the central endothelial cell layer. |
| NCT03971357 ↗ | Trial of Netarsudil for Acceleration of Corneal Endothelial Restoration | Terminated | Price Vision Group | Phase 2/Phase 3 | 2019-07-22 | Subjects with Fuchs dystrophy will be randomized to use either netarsudil or placebo eye drops to determine if the use of netarsudil accelerates migration of host peripheral corneal endothelial cells to restore the central endothelial cell layer. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for RHOPRESSA
Condition Name
Clinical Trial Locations for RHOPRESSA
Trials by Country
Clinical Trial Progress for RHOPRESSA
Clinical Trial Phase
Clinical Trial Sponsors for RHOPRESSA
Sponsor Name
